Yousefi Aldashi Sara, Saffari Zahra, Ebrahimi Shahmabadi Hasan, Akbarzadeh Azim
Islamic Azad University Faculty of Technical and Engineering, Science and Research Branch, Tehran, Iran.
Department of Pilot Nanobiotechnology, Pasteur Institute of Iran, Tehran, Iran.
Adv Pharm Bull. 2021 Feb;11(2):267-273. doi: 10.34172/apb.2021.039. Epub 2020 Aug 5.
This study aimed to evaluate the role of magnetic liposome nanoparticles (ML NPs) as a carrier for paclitaxel (PTX) for the treatment of ovarian cancer . Magnetic NPs (MNPs) were synthesized by chemical co-precipitation method. The resulting NPs were characterized in terms of size, size distribution, zeta potential, drug encapsulation efficiency (EE), drug release pattern, and cytotoxicity effects. The size and zeta potential of PTX-PEG-L and PTX-PEG-ML NPs were determined to be 296, 198 nm; -20, and -19 mV, respectively. Also, their drug encapsulation efficiencies were determined to be 97% and 96%, respectively. It was found that PTX-PEG-ML NPs, compared to PTX-PEG-L NPs, caused a reduction (11%) in the rate of drug release. The cytotoxicity of the drug-loaded NPs was assessed using 3-[4,5-dimethylthiazole-2-yl]-2,5-diphenyltetrazolium bromide (MTT) assay against human ovarian epithelial cancer (A2780CP) cells, and the results demonstrated that PTX-PEG-ML NPs caused higher cytotoxicity (by 14%) compared to PTX-PEG-L NPs (IC: 1.88 ± 0.09 and 2.142 ± 0.1 µM, respectively). Overall, the results of this study suggest that PTX-PEG-ML NPs could be considered as a therapeutic candidate for the treatment of ovarian cancer.
本研究旨在评估磁性脂质体纳米颗粒（ML NPs）作为紫杉醇（PTX）载体用于治疗卵巢癌的作用。通过化学共沉淀法合成磁性纳米颗粒（MNPs）。对所得纳米颗粒进行了尺寸、尺寸分布、zeta电位、药物包封率（EE）、药物释放模式和细胞毒性作用等方面的表征。PTX-PEG-L和PTX-PEG-ML纳米颗粒的尺寸和zeta电位分别测定为296、198 nm；-20和-19 mV。此外，它们的药物包封率分别测定为97%和96%。结果发现，与PTX-PEG-L纳米颗粒相比，PTX-PEG-ML纳米颗粒使药物释放速率降低了11%。使用3-[4,5-二甲基噻唑-2-基]-2,5-二苯基四氮唑溴盐（MTT）法评估载药纳米颗粒对人卵巢上皮癌（A2780CP）细胞的细胞毒性，结果表明，与PTX-PEG-L纳米颗粒相比，PTX-PEG-ML纳米颗粒具有更高的细胞毒性（高14%）（IC50分别为1.88±0.09和2.142±0.1 µM）。总体而言，本研究结果表明，PTX-PEG-ML纳米颗粒可被视为治疗卵巢癌的候选治疗药物。
